library.onepin.app/vesilute Peptide Education Library

Education only, not medical advice◆ 21+◆ Every dose is an example to finalize with a licensed provider

OnePin Peptide Library · Bioregulators

Bioregulators Khavinson bioregulator tetrapeptide Not FDA-approved · investigational

Vesilute

Vesilute Peptide

Khavinson bioregulator tetrapeptideVascular tissue regulatorEndothelial gene expression modulator

Vesilute (Lys-Glu-Asp-Trp) is a Khavinson bioregulator tetrapeptide targeting vascular tissue gene expression. It supports endothelial cell function, vascular wall integrity, and cardiovascular protective pathways. Complementary to Cardiogen (cardiac muscle) for comprehensive cardiovascular bioregulatory support.

Quick Start

Route

SubQ injection

Start low

5 mg daily

Frequency

Daily for 10-20 day course

Timing

No fasting required

SubQ injection, any time of day. 10-20 day courses, 2-3 cycles per year with 4-6 months between courses (Khavinson protocol). Pin alone or with other bioregulators only.

❋

Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.

Tiered Protocols · lowest first

Quick Start

Conservative start

5 mg daily · SubQ injection · Daily for 10-20 day course

Lowest starting point. Hold about a week to assess tolerance before stepping up.

5 mg daily

Daily for 10-20 day course

Standard

Bladder Bioregulation

10-20 mg · Oral · Daily

anecdotal · community

10-20 mg

Daily

Reconstitution CalculatorU-100

Vial strength

BAC water

Target dose

050100u

Draw to

— units

◆

How it works

Vesilute modulates gene expression in endothelial cells and vascular smooth muscle, supporting NO synthase expression, vascular wall integrity, and anti-atherogenic pathways.

What to expect

Early

Days 1–7

Days 1-10: Gene changes initiated.

Mid

Weeks 2–4

Weeks 2-8: Vascular gene programs established.

Later

Weeks 4–12

Months: Sustained vascular support.

Evidence

HumanPresent

AnimalPresent

In-vitroPresent

2013Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results · Khavinson VKh, Kuznik BI, Ryzhak GA, Advances in Gerontology ↗review

2013Peptide bioregulators: the new class of geroprotectors. Communication 1. Results of experimental studies · Khavinson VKh, Kuznik BI, Ryzhak GA, Advances in Gerontology ↗review

2010Peptide bioregulation of aging: results and prospects · Anisimov VN, Khavinson VKh, Biogerontology ↗review

The honest take

◆

Vascular rejuvenation

Bioregulatory gene expression modulation targeting endothelial and vascular smooth muscle cells.

Interactions & stacking

What's safe to combine, and what belongs in a separate pin.

Safe & synergistic

CardiogenVesilute targets vascular tissue, Cardiogen targets cardiac tissue. Comprehensive CV bioregulatory support. Run in sequence.

BPC-157Vesilute vascular gene expression + BPC-157 angiogenesis/NO. Complementary. Pin separately.

Keep separate

ALL (syringe)PIN ALONE.

GHK-CuCopper degrades bioregulators.

Side effects & safety

Commonly reported

Very well tolerated

Less common & notes

Monitor blood pressure if on CV medications.

Pharmacokinetics

Illustrative plasma concentration · 24 h

Half-life

0.5h

Peak · Tmax

0.05h

Elimination

2.5h

Activity

Weeks to months (epigenetic gene expression changes persist beyond dosing course)

Storage. Standard BAC water 2-8C. 21-28 days.

Regulatory status

Not FDA-approved. Research peptide.

Put it to work

Calculate, log & track

Open Vesilute straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.

Open Vesilute in the app →

Go deeper

The guide & community

The complete Vesilute walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.

Join the community ↗

Open in app Community